Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- MSM -1.6%
Other news:
- RNAC -17.6% (announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis; announces $130 million private placement equity financing; first patient dosed in phase 2 trial of descartes-08 in systematic lupus erythematosus)
- AZTR -8.5% (files mixed shelf and secondary stock offering)
- DHX -4.4% (to reduce workforce by around 7%)
- EBR -3.2% (concluded the sale of a 49% minority stake in the share capital of the 15 Special Purpose Companies)
- ARDX -3.2% (announces that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH, the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease Prospective Payment System Transitional Drug Add-on Payment Adjustment)
- YMAB -2.3% (appoints new CFO)
- LOGI -2% (proposes board member changes; company nominates new directors to board chairperson informs board of 2025 transition plan)
- ALVO -1.9% (issues new shares to holders of convertible bonds)
- ARCT -1.6% (provides updates for two of its programs)
- FERG -1.5% (provides notice of cancellation and replacement of uk listing in connection with new corporate structure to achieve a U.S. domicile)
- TLNE -1.1% (announces additional repurchase of common stock)
- CDXS -1% (to acquire disease compounds from Crosswalk Therapeutics)